Ulysses Neuroscience Ltd. is a Private R&D Organization having a more collaborative way of working with pharmaceutical companies. Our translational research investigates the molecular mechanisms leading to the synaptic pathology and neuroinflammatory events which may anticipate development of psychiatric and neurodegenerative disorders.
Axol Biosciences as a leading provider of iPSC reagents and services has a range of products which have an increasing utility in pharmacological and bio-pharmacological drug discovery for neuroimmunology. Recently we have merged with Censo Biotechnologies, a CRO specializing in development of custom models and candidate screening in neuroimmunology. Data will be presented on cell types such as iPSC derived microglia and astrocytes with regards to considerations and validation of those cell types and assays with relevance to the neuro-immunological disease modelling using iPSC-derived cells.
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery.
Proprietary MultiBrain® technology powers NSA’s simultaneous sectioning, and expertly guided staining, of up to 40 neuronal tissues in one MultiBrain® block, achieving uniform processing across all 40 tissues. Implementing NSA’s Large Format™ technology enables sectioning and staining of intact human brain hemispheres and yields comprehensive, uninterrupted vantage and analysis of the ultimate target. Coupling these mass production technologies with cutting-edge digital image capture and hosting, along with contemporary analysis tools increasingly powered by AI, rapidly produces rich data, and dramatically reduces R&D times.
Genomenon is a genomic health IT company that keeps pace with the constant advancements made in genomics and connects that research to patient DNA to help diagnose and treat patients with rare genetic diseases and cancer. Mastermind Genomic Landscapes inform pharmaceutical companies on precision medicine development, deliver genomic biomarkers for clinical trial target selection, and support CDx regulatory submissions with empirical evidence. Genomenon was named Company of the Year in Clinical Genomics Interpretation by Frost & Sullivan
Transpharmation is a preclinical CRO led by scientists. Established in 2010, Transpharmation has built on the international reputation and CNS drug discovery expertise of the founders. Transpharmation is recognised globally, and clients benefit from decades of experience in translational biology across multiple neuroscience preclinical services including EEG, cognition, epilepsy, pain, neurodegeneration and anxiety/mood disorders (including treatment-resistant depression and schizophrenia), together with a biomarker platform and human tissue capabilities. At Transpharmation, science will always remain our passion.